CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events: A Systematic Review and Meta-analysis

Holmes, Michael V., Perel, Pablo, Shah, Tina, Hingorani, Aroon D., Casas, Juan P.·2011·JAMA
DOI 10.1001/jama.2011.1880

Cited by (472)

Items 101–200 of 472

  1. Cost–Effectiveness of Using CYP2C19 Genotype to Guide Selection of Clopidogrel or Ticagrelor in Australia
    Michael Joseph Sorich, John David Horowitz, Wassana Sorich, Michael David Wiese, Brita A. K. Pekarsky, Jonathan D. Karnon · 2013 · Pharmacogenomics
  2. Network News: Powering Clinical Research
    Joseph V. Selby, Harlan M. Krumholz, Richard E. Kuntz, Francis S. Collins · 2013 · Science Translational Medicine
  3. Opportunities and Challenges in Cardiovascular Pharmacogenomics
    Dan M. Roden, Sara L. Van Driest, Quinn Stanton Wells, Jonathan D. Mosley, Joshua C. Denny, Josh F. Peterson · 2018 · Circulation Research
  4. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis
    Yusuke Yamaguchi, Takayuki Abe, Yuji Sato, Yumiko Matsubara, Takanori Moriki, Mitsuru Murata · 2012 · Platelets
  5. Pharmacogenetic testing: current evidence of clinical utility
    Jivan Moaddeb, Susanne B. Haga · 2013 · Therapeutic Advances in Drug Safety
  6. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction
    Jeffrey J. W. Verschuren, Helèn Boden, Judith A.M. Wessels, Bas L. van der Hoeven, Stella Trompet, Bastiaan T. Heijmans, Hein Putter, Henk‐Jan Guchelaar, Martin Jan Schalij, J. Wouter Jukema · 2012 · International Journal of Cardiology
  7. Reliable Biomarkers and Predictors of Schizophrenia and its Treatment
    Anilkumar Pillai, P.F. Buckley · 2012 · Psychiatric Clinics of North America
  8. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy
    Lisa Groß, Dietmar Trenk, Claudius Jacobshagen, Anne Krieg, Meinrad Gawaz, Steffen Maßberg, Monika Baylacher, Dániel Aradi, Fabian Stimpfle, Julia Hromek et al. · 2018 · Thrombosis and Haemostasis
  9. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI
    Jean‐Sébastien Hulot, Bernard Chevalier, Loïc Belle, Guillaume Cayla, Khalifé Khalifé, Francois Funck, Romain Berthier, Christophe A. Piot, Muriel Tafflet, Gilles Montalescot et al. · 2020 · JACC: Cardiovascular Interventions
  10. Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
    Haruhiko Hoshino, Ḱazunori Toyoda, Katsuhiro Omae, Noriyuki Ishida, Shinichiro Uchiyama, Kazumi Kimura, Nobuyuki Sakai, Yasushi Okada, Kortaro Tanaka, Hideki Origasa et al. · 2021 · Stroke
  11. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study
    for the ARCTIC investigators, Jean‐Philippe Collet, Jean‐Sébastien Hulot, Thomas Cuisset, Grégoire Rangé, Guillaume Cayla, Eric VAN BELLE, Simon Elhadad, Hélène Rousseau, Pierre François Sabouret et al. · 2015 · European Journal of Clinical Pharmacology
  12. Exploratory Planning and Implementation of a Pilot Pharmacogenetic Program in a Community Pharmacy
    Shanna K. O’Connor, Stefanie P. Ferreri, Natasha M. Michaels, Angelo J. Greco, Anthony J. Viera, Hawazin Faruki, Howard L. McLeod, Mary W Roederer · 2012 · Pharmacogenomics
  13. Clopidogrel Use Is Associated With an Increased Prevalence of Cerebral Microbleeds in a Stroke‐Free Population: The Rotterdam Study
    Sirwan K.L. Darweesh, Maarten J.G. Leening, Saloua Akoudad, Daan W. Loth, Albert Hofman D, M. Arfan Ikram, Meike Willemijn Vernooij, Bruno H. Ch. Stricker · 2013 · Journal of the American Heart Association
  14. Pharmacogenomics in Asians: Differences and similarities with other human populations
    Mohitosh Biswas, Pimonpan Jinda, Chonlaphat Sukasem · 2023 · Expert Opinion on Drug Metabolism & Toxicology
  15. Role of phenotypic and genetic testing in managing clopidogrel therapy
    Noel Chan, John W. Eikelboom, Jeffrey S. Ginsberg, Mandy N. Lauw, Thomas Vanassche, Jeffrey Ian Weitz, Jack Hirsh · 2014 · Blood
  16. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)
    Cormac Thomas O'Connor, Thomas John Kiernan, Bryan P. Yan · 2017 · Expert Opinion on Drug Metabolism & Toxicology
  17. Platelet Function and Genetic Testing
    Dominick Joseph Angiolillo, José Luis Ferreiro, Matthew J. Price, Ajay Jayant Kirtane, Gregg W. Stone · 2013 · Journal of the American College of Cardiology
  18. Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race‐Conscious Medicine
    Brittney H. Davis, Nita A. Limdi · 2021 · Clinical Pharmacology & Therapeutics
  19. Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art
    Stephanie A. Ross, Kristi Krebs, Guillaume Paré, Lili A. Milani · 2022 · Stroke
  20. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers
    Christian Funck‐Brentano, Jean Szymezak, Olivier Steichen, Dominique Ducint, Mathiéu Molimard, Véronique Remones, Michel Azizi, Pascale Gaussem · 2013 · Archives of cardiovascular diseases
  21. Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel
    W‐P Zhong, Heming Wu, J‐Y Chen, X. LI, H‐M Lin, Bing Zhang, Z‐W Zhang, D‐L Ma, Shufeng Sun, H‐P Li et al. · 2016 · Clinical Pharmacology & Therapeutics
  22. Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?
    Nina P. Paynter, Paul M. Ridker, Daniel I. Chasman · 2016 · Circulation Research
  23. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes
    Zenko Nagashima, Kengo Tsukahara, Satoshi Morita, Tsutomu Endo, Teruyasu Sugano, Kiyoshi Hibi, Hideo Himeno, Kazuki Fukui, Satoshi Umemura, Kazuo Kimura · 2013 · Journal of Cardiology
  24. Genetic variation of platelet function and pharmacology: An update of current knowledge
    Elke Schaeffeler, Elke Schaeffeler, Meinrad Gawaz, Matthias Georg Schwab, Tobias Geisler · 2013 · Thrombosis and Haemostasis
  25. Cardiovascular pharmacogenomics: current status and future directions
    Dan M. Roden · 2015 · Journal of Human Genetics
  26. Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?
    Christina G. Tise, Alan R. Shuldiner · 2013 · Journal of Human Genetics
  27. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome
    Wenxing Peng, Xiujin Shi, Xiaoyu Xu, Lin Yang · 2019 · Cardiovascular Therapeutics
  28. Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis
    Mark J. Canet, Nathan J. Cherrington · 2014 · Expert Opinion on Drug Metabolism & Toxicology
  29. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists
    Morten Würtz, Marie Lordkipanidzé, Erik Lerkevang Grove · 2013 · Journal of Thrombosis and Haemostasis
  30. The pharmacogenetic control of antiplatelet response: candidate genes andCYP2C19
    Yao Yang, Joshua P. Lewis, Jean‐Sébastien Hulot, Stuart Alexander Scott · 2015 · Expert Opinion on Drug Metabolism & Toxicology
  31. Anatomical distribution and expression of CYP in humans: Neuropharmacological implications
    Daniela Fanni, Federica Pinna, Clara Gerosa, Pasquale Paribello, Bernardo Carpiniello, Gavino Faa, Mirko Manchia · 2021 · Drug Development Research
  32. Pharmacogenetics of P2Y 12 receptor inhibitors
    Cameron D. Thomas, Alexis K. Williams, Craig R. Lee, Larisa H. Cavallari · 2023 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  33. Reduced Clopidogrel Metabolism in a Multiethnic Population: Prevalence and Rates of Recurrent Cerebrovascular Events
    Ilana Spokoyny, Nobl Barazangi, Victor Jaramillo, Jack Rose, Xiaomeng Charlene Chen, Christine Wong, David Tong · 2013 · Journal of Stroke and Cerebrovascular Diseases
  34. Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting
    John Tazare, Richard Wyss, Jessica Myers Franklin, Liam L Smeeth, Stephen J. W. Evans, Shirley V. Wang, Sebastian Schneeweiß, Ian Douglas, Joshua J. Gagne, Elizabeth Williamson · 2022 · Pharmacoepidemiology and Drug Safety
  35. Pharmacogenomics and Implications for Nursing Practice
    Dennis J. Cheek, Lisa M. Bashore, Daniel Alan Brazeau · 2015 · Journal of Nursing Scholarship
  36. Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia
    Yohei Numasawa, Mitsuaki Sawano, Ryoma Fukuoka, Kentaro Ejiri, Toshiki Kuno, Satoshi Shoji, Shun Kohsaka · 2020 · Journal of Clinical Medicine
  37. Challenges and Limitations in the Interpretation of Systematic Reviews: Making Sense of Clopidogrel and CYP2C19 Pharmacogenetics
    Michael Joseph Sorich, Thomas M. Polasek, Michael David Wiese · 2013 · Clinical Pharmacology & Therapeutics
  38. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease
    Udaya S. Tantry, Young‐Hoon Jeong, Eliano Pio Navarese, Jacek Kubica, Paul Alfred Gurbel · 2013 · Expert Review of Cardiovascular Therapy
  39. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays
    Argirios Ε. Tsantes, Ignatios Ikonomidis, Ioannis Papadakis, Stefanos Bonovas, Argiri Gialeraki, Christine Kottaridi, Elias S. Kyriakou, Styliani I. Kokoris, Panagiota Douramani, Petros Kopterides et al. · 2013 · Thrombosis Research
  40. Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.
    Ku-Lang Chang, Kristin Wiisanen Weitzel, Siegfried O. Schmidt · 2015 · PubMed
  41. Using nationwide ‘big data’ from linked electronic health records to help improve outcomes in cardiovascular diseases: 33 studies using methods from epidemiology, informatics, economics and social science in the ClinicAl disease research using LInked Bespoke studies and Electronic health Records (CALIBER) programme
    Harry Hemingway, Gene Solomon Feder, Natalie K. Fitzpatrick, Spiros Denaxas, Anoop D Shah, Adam Timmis · 2017 · Programme Grants for Applied Research
  42. Clopidogrel‐associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients
    Xiaoye Li, Zi Wang, Qibing Wang, Qing Xu, Qianzhou Lv · 2018 · Basic & Clinical Pharmacology & Toxicology
  43. CYP2C19 Phenotype, Stent Thrombosis, Myocardial Infarction, and Mortality in Patients with Coronary Stent Placement in a Chinese Population
    Xiang Xie, Yi‐Tong Ma, Yi‐Ning Yang, Xiao‐Mei Li, Xiang Ma, Zhen-Yan Fu, Ying‐Ying Zheng, Bang‐Dang Chen, Fen Liu · 2013 · PLoS ONE
  44. Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping
    Pierre Fontana, Marco Cattaneo, Christophe Combescure, Jean‐Luc Reny · 2013 · Journal of the American Heart Association
  45. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention
    Samuel G. Johnson, Don Gruntowicz, Theresa Chua, Robert Morlock · 2015 · Journal of Managed Care & Specialty Pharmacy
  46. Pharmacogenomics, precision medicine, and implications for anesthesia care
    Alan D. Kaye, Thomas Mahakian, Aaron Joshua Kaye, Andrew Pham, Brendon M. Hart, Sonja A. Gennuso, Elyse M. Cornett, Rodney Allanigue Gabriel, Richard D. Urman · 2018 · Best practice & research. Clinical anaesthesiology
  47. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention
    Vardhaman Patel, Fang‐Ju Lin, Olaitan Ojo, Sapna Rao, Shengsheng Yu, Lin Zhan, Daniel R. Touchette · 2014 · Pharmacy Practice
  48. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis
    Xiaowen Hou, Jingpu Shi, Hao Xuan Sun · 2014 · European Journal of Clinical Pharmacology
  49. Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?
    Irfan Zeb, Nassim Rostane Krim, Jonathan N. Bella · 2018 · Expert Review of Cardiovascular Therapy
  50. Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients
    Hefei Fu, Pan Hu, Chunmei Ma, Fei Peng, Zhiyi He · 2020 · Medicine
  51. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention
    Melissa Mejin, Wen Ni Tiong, Lana Yin Hui Lai, Lee Len Tiong, Mohamad Adam Bujang, Siaw San Hwang, Tiong Kiam Ong, Alan Yean Yip Fong · 2013 · International Journal of Clinical Pharmacy
  52. Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present
    Diana Adrienne Gorog, Tobias Geisler · 2020 · Thrombosis and Haemostasis
  53. Applied Pharmacogenomics in Cardiovascular Medicine
    Peter Weeke, Dan M. Roden · 2013 · Annual Review of Medicine
  54. Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests
    David A. Khan · 2016 · Journal of Allergy and Clinical Immunology
  55. Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases
    Anu Radha Sharma, Manik Vohra, Vaibhav Shukla, Vasudeva Guddattu, Abdul Razak UK, Ranjan K Shetty, Shashikiran Umakanth, Kapaettu Satyamoorthy, Padmalatha S. Rai · 2020 · Life Sciences
  56. Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome.
    Yan Yan, Xiao Wang, Jingyao Fan, Shaoping Nie, Sergio Raposeiras‐Roubín, Emad Abu‐Assi, Josè P.S. Henriques, Fabrizio D’Ascenzo, Jorge Saucedo, José Ramón González‐Juanatey et al. · 2016 · PubMed Central
  57. Pharmacogenetics of Antiplatelets and Anticoagulants: A Report on Clopidogrel, Warfarin and Dabigatran
    Stephanie A. Ross, Guillaume Paré · 2013 · Pharmacogenomics
  58. P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application
    Francesco Nappi · 2024 · International Journal of Molecular Sciences
  59. Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation
    Noriaki Tabata, Seiji Hokimoto, Tomonori Akasaka, Yuichiro Arima, Koichi Kaikita, Naoki Kumagae, Kazunori Morita, Hiroko Miyazaki, Kentaro Oniki, Kazuko Nakagawa et al. · 2014 · Thrombosis Research
  60. Advances in the monitoring of anti-P2Y12 therapy
    Paul J. Harrison · 2012 · Platelets
  61. PAR-1 antagonists: current state of evidence
    Saurav Chatterjee, Abhishek Sharma, Debabrata Mukherjee · 2012 · Journal of Thrombosis and Thrombolysis
  62. A genetic polymorphism in P2RY1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy
    Yu Ueda, Ronald H. L. Li, Nghi H. Nguyen, Eric S. Ontiveros, Samantha L. Kovacs, Maureen S. Oldach, Karen M. Vernau, Michael H. Court, Joshua A. Stern · 2021 · Scientific Reports
  63. Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk
    Yunosuke Matsuura, Kohei Moribayashi, Koichi Kaikita · 2022 · Journal of Atherosclerosis and Thrombosis
  64. Pharmacogenomic Assessment of Mexican and Peruvian populations
    Sharon Marsh, Cristi R. King, Derek J. Van Booven, Jane Yen Revollo, Robert H. Gilman, Howard L. McLeod · 2015 · Pharmacogenomics
  65. The Triangulation WIthin a STudy (TWIST) framework for causal inference within pharmacogenetic research
    Jack Bowden, Luke C. Pilling, Deniz Türkmen, Chia‐Ling Kuo, David R. Melzer · 2021 · PLoS Genetics
  66. Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation
    Masakatsu Nishikawa, Yoshihiro Takeda, Naoei Isomura, Takashi Tanigawa, Mamoru Nanasato, Kengo Tsukahara, Kazuo Kimura, Tadateru Takayama, Atsushi Hirayama, Masafumi Kato et al. · 2019 · Journal of Atherosclerosis and Thrombosis
  67. CYP2C19 Genotype and Cardiovascular Events
    Mark R. Vesely · 2012 · JAMA
  68. Cardiovascular precision medicine – A pharmacogenomic perspective
    Sandosh Padmanabhan, Clea du Toit, Anna F. Dominiczak · 2023 · Cambridge Prisms Precision Medicine
  69. Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention.
    Yu Chen, Xiaohong Huang, Yong Cheng Tang, Yuquan Xie, Yachen Zhang · 2015 · Europe PMC (PubMed Central)
  70. Advances in Our Understanding of “Resistance” to Antiplatelet Agents for Prevention of Ischemic Stroke
    Philip B. Gorelick, Muhammad Umar Farooq · 2013 · Stroke Research and Treatment
  71. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina
    Yuichiro Arima, Seiji Hokimoto, Tomonori Akasaka, Koichi Mizobe, Koichi Kaikita, Kentaro Oniki, Kazuko Nakagawa, Hisao Ogawa · 2014 · Journal of Cardiology
  72. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study
    Faruk Saydam, İrfan Değirmenci, Alparslan Birdane, Mahmut Özdemir, Taner Ulus, Cansu Özbayer, Ertuğrul Çolak, Necmi Ata, Hasan Veysi Güneş · 2017 · Basic & Clinical Pharmacology & Toxicology
  73. Increased plasma cathepsin S and trombospondin-1 in patients with acute ST-segment elevation myocardial infarction
    Rahel Befekadu, Kjeld Christiansen, Anders Olof Larsson, Magnus Grenegård · 2018 · Cardiology Journal
  74. Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism
    Jun-Feng Su, XIAO-HUI HU, CHENG-YAN LI · 2014 · Experimental and Therapeutic Medicine
  75. Clopidogrel, CYP2C19, and a Black Box
    Neville F. Ford, Dirk Taubert · 2013 · The Journal of Clinical Pharmacology
  76. CYP2C19 Genotype and Cardiovascular Events
    Eric J. Topol · 2012 · JAMA
  77. Pharmacogenetics at 50: Genomic Personalization Comes of Age
    Thomas Jacob Urban, David B. Goldstein · 2012 · Science Translational Medicine
  78. Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
    Alfredo Mauriello, Antonia Ascrizzi, Riccardo Molinari, Luigi Falco, Alfredo Caturano, Antonello D’Andrea, Vincenzo Russo · 2023 · Genes
  79. Aspirin and Clopidogrel for Prevention of Ischemic Stroke
    Ruth M. Thomson, David C. Anderson · 2013 · Current Neurology and Neuroscience Reports
  80. Genetic mutations in PEAR1 associated with cardiovascular outcomes in Chinese patients with acute coronary syndrome
    Xiaoyan Nie, Jun-lei Li, Si-bei Qin, Yu Fu, Guang-kai Liang, Luwen Shi, Hong Shao, Jian Liu, Yun Lu · 2018 · Thrombosis Research
  81. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis
    Lukai Zheng, Chunsong Yang, Lingbao Xiang, Zilong Hao · 2019 · Biomarkers
  82. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome
    Kibum Kim, Daniel R. Touchette, Larisa H. Cavallari, Amer Kasim Ardati, Robert J. DiDomenico · 2019 · Cardiovascular Drugs and Therapy
  83. Why Randomized Controlled Trials Are Needed to Accept New Practices: 2 Medical Worldviews
    Vinay K. Prasad · 2013 · Mayo Clinic Proceedings
  84. Pharmacogenetics of Clopidogrel
    Naveen L. Pereira, Jeffrey Benjamin Geske, Manuel Mayr, Svati Hasmukh Shah, Charanjit S. Rihal · 2016 · Circulation Cardiovascular Genetics
  85. Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis
    Jafrin, Sarah, Naznin, Nura Ershad, Reza, Md. Sharif, Aziz, Md. Abdul, Islam, Mohammad Safiqul · 2021 · European Journal of Internal Medicine
  86. Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population
    Yi‐Chung Lee, Yi‐Chu Liao, Feng‐Chi Chang, Hui‐Chi Huang, Jui-Yao Tsai, Chih‐Ping Chung · 2019 · Journal of the Chinese Medical Association
  87. GENETICS/GENOMICS AND DRUG EFFECTS
    F. Heller · 2013 · Acta Clinica Belgica
  88. Challenges in pharmacogenetics
    Ingolf Cascorbi, Oliver Bruhn, Anneke Nina Werk · 2013 · European Journal of Clinical Pharmacology
  89. Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies
    Michael Joseph Sorich, Michael D Coory · 2013 · The Pharmacogenomics Journal
  90. Effects of P2Y12 Receptor Inhibition in Patients With ST-Segment Elevation Myocardial Infarction
    Dimitrios K. Alexopoulos, Ioanna Xanthopoulou, John A. Goudevenos · 2014 · The American Journal of Cardiology
  91. Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention
    Anna Komosa, Jolanta Maria Siller-Matula, Maciej Lesiak, Michał Michalak, Jadwiga Kowal, Maciej Mączyński, Andrzej Siniawski, Tatiana Mularek‐Kubzdela, Stephen R. Wisniewski, Stefan Grajek · 2015 · Thrombosis Research
  92. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
    Si‐qi Lyu, Yanmin Yang, Jun Zhu, Juan Wang, Shuang Wu, Han Zhang, Xing‐hui Shao, Jiameng Ren · 2020 · Platelets
  93. Pharmacogenetics of Clopidogrel
    Stephen A. O’Connor, Jean‐Sébastien Hulot, Johanne Silvain, Guillaume Cayla, Gilles Montalescot, Jean‐Philippe Collet · 2012 · Current Pharmaceutical Design
  94. Genetic Determinants of P2Y12 Inhibitors and Clinical Implications
    Larisa H. Cavallari, Aniwaa Owusu Obeng · 2016 · Interventional Cardiology Clinics
  95. Point of care CYP2C19 genotyping after percutaneous coronary intervention
    Linnea M. Baudhuin, Laura J. Train, Shaun G. Goodman, Gary E. Lane, Ryan J. Lennon, Verghese Mathew, Vishakantha Murthy, Tamim M. Nazif, Derek Y F So, John P. Sweeney et al. · 2022 · The Pharmacogenomics Journal
  96. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice
    Payman Shahabi, Marie‐Pierre Dubé · 2015 · International Journal of Cardiology
  97. Clopidogrel and warfarin pharmacogenetic tests
    Mohamed H. Shahin, Julie A. Johnson · 2013 · Current Opinion in Cardiology
  98. Pharmacogenomics
    Yogita Ghodke‐Puranik, Jatinder Kaur Lamba · 2016 · Elsevier eBooks
  99. New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin
    Xiaomin Liu, Huaiqian Xu, Huaiqian Xu, Qingshan Geng, Wai-Ho Mak, Fei Ling, Zheng Su, Fang� Yang, Tao Zhang, Jiyan Chen et al. · 2021 · The Pharmacogenomics Journal
  100. CYP2C19 drug-drug and drug-gene interactions in ED patients
    Hanna K. Flaten, Howard S. Kim, Jenny A. Campbell, Lisa J Hamilton, Andrew A. Monte · 2015 · The American Journal of Emergency Medicine